# A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

> **NCT00479336** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 104 (actual)

## Conditions studied

- Cirrhosis

## Interventions

- **DRUG:** OPC-41061 7.5mg
- **DRUG:** OPC-41061 placebo
- **DRUG:** OPC-41061 15mg
- **DRUG:** OPC-41601 30mg

## Key facts

- **NCT ID:** NCT00479336
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2014-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479336, "A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00479336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*